Gestational Exposure to Type of Antidepressants Associated With Adolescent Offspring Depression
A study to be published in the May 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) reports that use of certain antidepressants during pregnancy can result in offspring depression by early adolescence.
Using national register data from Finland, researchers found that children exposed to selective serotonin reuptake inhibitors (SSRIs) during gestation had more chance of being diagnosed with depression after age 12, reaching a cumulative incidence of 8.2% by age 15. For children exposed to maternal psychiatric illness but no antidepressants, the incidence was 1.9%. Rates of anxiety, autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) diagnoses did not differ significantly between the two groups. Comparing SSRI-exposed children to children of mothers with neither antidepressant use nor psychiatric diagnosis, researchers found the rates were significantly elevated for each outcome.
Animal studies already demonstrated that exposure to SSRIs during early brain development can result in depression-like behavior in adolescence; this is the first study that follows children beyond childhood to monitor the development of depressive disorders, which typically emerge after puberty has started. The increasing rate of SSRI prescriptions to pregnant women since their introduction 30 years ago makes the study of affected children particularly urgent. Today 6% of pregnant women in the US and 4% in Finland are on SSRIs at some stage of pregnancy.
To investigate whether using SSRIs during pregnancy is associated with offspring psychiatric disorders, researchers from Columbia University, New York State Psychiatric Institute, and Sackler Institute for Developmental Psychobiology joined forces with researchers from the University of Turku and Helsinki in Finland. They examined psychiatric diagnoses, including depression, anxiety, ASD, and ADHD, in the offspring of nearly 16,000 mothers who had used SSRIs during pregnancy between 1996 and 2010. Children in this cohort ranged in age from 0 to 15 years old. Because maternal psychiatric illness can affect offspring neurodevelopment in the absence of SSRIs, primary comparisons were made between offspring of the SSRI group and offspring of mothers with a psychiatric disorder diagnosis but no antidepressant use.
“The results are in line with studies in rodents, suggesting that SSRI use during pregnancy increases the risk of offspring depression,’’ Dr. Heli Malm, the first author of the study, said. “However, the oldest subjects had only just entered the age of risk for depression, and we know that mood disorders typically emerge after the onset of puberty. Further research is therefore urgently needed to follow these children as they get older to substantiate our findings. Until confirmed, these findings must be balanced against the adverse consequences of untreated maternal depression. While some women with mild to moderate depression may do well coming off antidepressants during pregnancy, severe depression when left untreated can lead to serious consequences in the mother and can have direct and indirect adverse effects on the pregnancy, the fetus, and the child.”
While it might seem reassuring that the results showed no elevated risk of ASD and ADHD for SSRI-exposed offspring, there may still be significant effects on offspring risk for depression. Dr. Andre Sourander, co-author of the study, added: “Further studies should determine whether the developing fetus is particularly sensitive to the effects of SSRIs in different trimesters, whether some medications may be safer than others for the fetus, and whether evidence-based psychotherapies could be better utilized to maximize maternal benefits while minimizing risk to the long-term health of the developing fetus.”
Notes for editors
The article is “Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study” by Heli Malm, Alan S. Brown, Mika Gissler, David Gyllenberg, Susanna Hinkka-Yli-Salomäki, Ian W. McKeague, Myrna Weissman, Priya Wickramaratne, Miia Artama, Jay A. Gingrich, and Andre Sourander (doi: 10.1016/j.jaac.2016.02.013). It appears in the Journal of the American Academy of Child and Adolescent Psychiatry, Volume 55, Issue 5 (2016), published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact Mary Billingsley at +1 202 587 9672 or email@example.com. Journalists wishing to interview the authors may contact Dr. Heli Malm at firstname.lastname@example.org.
All articles published in JAACAP are embargoed until the day they are published as in-press corrected proofs online at http://jaacap.org/inpress. Articles cannot be publicized as in-press accepted manuscripts. Contents of the publication should not be released to or by the media or government agencies prior to the embargo date.
Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families. www.jaacap.com
The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
JAACAP Editorial Office
+1 202 587 9672